The World Health Organization-recommended single-dose schedule for human papillomavirus (HPV) vaccination is expected to bring operational efficiencies and lower costs to country immunization programs.

PATH conducted a study on behalf of the HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium to obtain insights into how switching to a single-dose schedule has impacted HPV vaccination programs in low- and middle-income countries and to gather insights for ongoing program planning and sustainability with a single-dose schedule. PATH conducted 35 semi-structured key informant interviews with national and subnational stakeholders in Burkina Faso, Ethiopia, and Solomon Islands to explore the operational aspects of switching from a two-dose to a one-dose HPV vaccination schedule across key thematic areas of the immunization program. This report shares high-level results from the study.